SCHEMBL120746

SCHEMBL120746

CCOC(=O)C(=CN(C)C)C(C)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.64
CYP2C9 P11712 2/20 0.53
MAPT P10636 8/20 0.50
MEN1 O00255 7/20 0.50
KMT2A Q03164 7/20 0.50
USP2 O75604 1/20 0.50
IDE P14735 1/20 0.50
TNNI3 P19429 1/20 0.50
TNNT2 P45379 1/20 0.50
TNNC1 P63316 1/20 0.50
NPSR1 Q6W5P4 3/20 0.48
ALDH1A1 P00352 6/20 0.45
GAA P10253 3/20 0.45
CYP2D6 P10635 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 4/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
S1PR4 O95977 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120745 1.00 GLO1 (0.64) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL5902214 1.00 GLO1 (0.64) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL3230226 0.90 CYP2C9 (0.58) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL23065899 0.87 GLO1 (0.50) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL15565954 0.84 CYP2C9 (0.53) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL365557 0.84 CYP2C9 (0.53) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL932967 0.84 CYP2C9 (0.53) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL932966 0.84 CYP2C9 (0.53) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL4099809 0.82 CYP2C9 (0.51) GLO1CYP2C9MAPTMEN1KMT2A
SCHEMBL18733161 0.82 CYP2C9 (0.51) GLO1CYP2C9MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118164918-A Synthesis method of 2, 4-dimethyl-5-aminopyrimidine 南通大学 2024-06-11 CN claimed
CN-118026936-A Diphenylethylene bactericide containing pyrazole ring and preparation method and application thereof 华南理工大学 2024-05-14 CN claimed
US-12630563-B2 Macrocyclic RIP2-kinase inhibitors ONCODESIGN S.A. (FR) 2026-05-19 US disclosed
US-20260125396-A1 MACROCYCLIC RIP2-KINASE INHIBITORS ONCODESIGN S.A. (FR) 2026-05-07 US disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
US-20260007680-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2026-01-08 US disclosed
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 EP disclosed
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
US-20250066361-A1 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-02-27 US disclosed
CN-113444102-B Fused tetracyclic compound and application thereof in medicines 广东东阳光药业股份有限公司 2025-02-25 CN disclosed
CN-115698020-B Macrocyclic RIP 2-kinase inhibitors 昂科迪塞恩精密医药公司(OPM) 2025-02-25 CN disclosed
EP-0733033-B1 PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS ZENECA LTD (GB) 1999-12-22 EP disclosed
US-5888941-A Carbozamides with antifungal activity J. URIACH & CIA. S.A. (ES) 1999-03-30 US disclosed
EP-0783502-A1 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY J. URIACH & CIA. S.A. (ES) 1997-07-16 EP disclosed
WO-1997005131-A1 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY J. URIACH & CIA. S.A. (ES) 1997-02-13 WO disclosed
US-5321002-A Herbicidal derivatives of 2-(1-aryl-4-cyano-5-pyrazolylmethyleneiminooxy)alkanoic acids FMC CORPORATION (US) 1994-06-14 US disclosed
US-5250504-A Pre- and postemergence FMC CORPORATION (US) 1993-10-05 US disclosed
US-5241099-A PROCESS FOR THE PREPARATION OF AMINOMETHYLENE COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 1993-08-31 US disclosed
US-5198014-A Herbicidal beta-pyrazolylacrylic acid compound FMC CORPORATION (US) 1993-03-30 US disclosed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260007680-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B GLO1 3764/4885CYP2C9 1080/4885MAPT 4801/4885
US-20250066361-A1 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) HAVCR2, HMBS, HBS1L GLO1 2987/4885CYP2C9 91/4885MAPT 1335/4885
US-20260125396-A1 MACROCYCLIC RIP2-KINASE INHIBITORS RIPK1, RIPK2, RIPK4 GLO1 1907/4885CYP2C9 4334/4885MAPT 1956/4885
US-12630563-B2 Macrocyclic RIP2-kinase inhibitors RIPK1, RIPK2, RIPK3 GLO1 3733/4885CYP2C9 4772/4885MAPT 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.